7,577 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 7,577 shares of the company’s stock, valued at approximately $322,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in GeneDx in the 2nd quarter valued at $34,000. nVerses Capital LLC bought a new stake in GeneDx in the 2nd quarter valued at $50,000. CWM LLC bought a new stake in GeneDx in the 3rd quarter valued at $89,000. SG Americas Securities LLC bought a new stake in GeneDx in the 3rd quarter valued at $198,000. Finally, Palumbo Wealth Management LLC bought a new stake in GeneDx in the 3rd quarter valued at $287,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Stock Up 9.2 %

Shares of NASDAQ WGS opened at $78.71 on Friday. The firm’s 50-day simple moving average is $59.61 and its 200 day simple moving average is $39.55. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -25.31 and a beta of 2.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12-month low of $1.41 and a 12-month high of $89.11.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm’s quarterly revenue was up 44.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.82) EPS. On average, research analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on WGS shares. Wells Fargo & Company boosted their price target on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. BTIG Research boosted their target price on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Craig Hallum boosted their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Finally, TD Cowen boosted their target price on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and an average target price of $59.33.

Insider Buying and Selling

In other GeneDx news, CFO Kevin Feeley sold 895 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35. Following the transaction, the chief financial officer now directly owns 39,910 shares in the company, valued at approximately $1,330,200.30. This represents a 2.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87. Following the transaction, the chief executive officer now owns 95,457 shares in the company, valued at approximately $3,181,581.81. The trade was a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,090 shares of company stock worth $81,094,171 in the last 90 days. Corporate insiders own 27.30% of the company’s stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.